Isolation, Characterization and In-Silico Study of Conotoxin Protein from Conus loroisii and Its Anti-cancer Activity

Cytotoxicity and apoptosis induction of the marine Conus flavidus venom in HepG2 cancer cell line

Cancer is still an area of continuous research for finding more effective and selective agents, so our study aimed to explore new anticancer medicines from Cone snails' venoms as marine natural products with promising biological activities. Venoms from seven cone snails collected from two locations on the Red Sea coast (Marsa Alam (Ma) and Hurghada (Hu)) were extracted and subjected to SDS for protein concentrations. The venoms of C. vexillum (Ma), C. vexillum (Hu), and C. flavidus were found to have the highest protein concentrations (2.66, 2.618, and 2.611 mg/mL, respectively). The venom of C. vexillum (Ma) was found to be cytotoxic against the lung cancer cell line A549 (IC50 = 4.511 ± 0.03 µg/mL). On the other hand, the venom of C. flavidus showed a strong cytotoxic effect on both liver and lung cancer cell lines (IC50 = 1.593 ± 0.05 and 7.836 ± 0.4 µg/mL, respectively) when compared to their normal cell lines. Investigating the apoptotic cell death of C. flavidus venom on HepG2 cell lines, it showed total apoptotic cell death by 22.42-fold compared to untreated control and arresting the cell cycle at G2/M phase. Furthermore, its apoptotic cell death in HepG2 cells was confirmed through the upregulation of pro-apoptotic markers and down-regulation of Bcl-2 in both gene and protein expression levels. These findings confirmed the cytotoxic activity of C. flavidus venom through apoptotic cell death in HepG2 cells. So, a detailed study highlighting its structure and molecular target for developing new anticancer agents from natural sources is required.Communicated by Ramaswamy H. Sarma.

A doxorubicin-platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells

In recent years, the development of a nano-conjugate system for drug delivery applications has gained attention among researchers. Keeping this in mind, in this study, we developed a doxorubicin-platinum conjugate system that targeted breast cancer cell lines. To achieve this, we developed platinum nanoparticles using polyvinylpyrrolidone (PVP). High resolution-transmission electron microscopy (HR-TEM) revealed the occurrence of octopod-shaped platinum nanoparticles. Subsequently, doxorubicin (DOX) was conjugated on the surface of the as-prepared platinum octopods via an in situ stirring method. The physicochemical characterization of the doxorubicin-platinum conjugate system revealed that the PVP of PtNPs interacts with the NH2 group of doxorubicin via electrostatic interaction/hydrogen bonding. Besides, the doxorubicin-platinum conjugate system exhibited a sustained drug release profile within the cancer cells. Furthermore, the evaluation of the in vitro anticancer efficacy of the doxorubicin-platinum conjugate system in breast cancer cells (MCF-7 and MDA-MB-231) unveiled the induction of apoptosis via intracellular ROS and DNA damage, rather than free DOX and PtNPs. Remarkably, we also perceived that the doxorubicin-platinum conjugate system was strong enough to down-regulate the PI3K/AKT signalling pathway. As a result, the tumour suppressor gene PTEN was activated, which led to the stimulation of a mitochondrion-based intrinsic apoptotic pathway and its downstream caspases, triggering cell death. Hence, our findings suggested that a biologically stable doxorubicin-platinum conjugate system could be an imperative therapeutic agent for anticancer therapy in the near future.